His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
